Cipla surges with arm acquiring prescription drug ZEMDRI from Achaogen

25 Jul 2019 Evaluate

Cipla is currently trading at Rs. 531.30, up by 12.55 points or 2.42% from its previous closing of Rs. 518.75 on the BSE.

The scrip opened at Rs. 519.80 and has touched a high and low of Rs. 535.65 and Rs. 519.40 respectively. So far 3933 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.

Last one week high and low of the scrip stood at Rs. 551.95 and Rs. 517.00 respectively. The current market cap of the company is Rs. 41805.44 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 41.84% and 21.46% respectively.

Cipla’s wholly-owned subsidiary -- Cipla USA Inc. has acquired the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. in a Chapter 11, US Bankruptcy Code auction of Achaogen’s assets. Cipla USA has acquired worldwide rights of ZEMDRI (excluding Greater China) with its allied assets and limited liabilities.

ZEMDRI is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1356.95 -57.85 (-4.09%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.